Open AccessTreating more with less: Effectiveness and event outcomes of antituberculosis fixed-dose combination drug versus separate-drug formulation (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide) for pulmonary tuberculosis patients in real-world clinical practice
Author(s) -
Jacqueline Mui Lan Lai,
Su Lan Yang,
Richard Avoi
Publication year - 2019
Publication title -
journal of global infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.437
H-Index - 25
eISSN - 0974-8245
pISSN - 0974-777X
DOI - 10.4103/jgid.jgid_50_18
Subject(s) - medicine , pyrazinamide , ethambutol , rifampicin , isoniazid , sputum , propensity score matching , tuberculosis , fixed dose combination , sputum culture , surgery , pathology
Conventionally, a combination of four separate drugs (ethambutol, isoniazid, rifampicin, and pyrazinamide [EHRZ]) is the first-line pharmacotherapy for pulmonary tuberculosis (TB). In recent years, fixed-dose combination (FDC) formulation, where a single tablet contains the active ingredients of four aforementioned drugs, is gaining popularity due to its ease of administration.